Kura Oncology, Inc. (KURA) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US50127T1097
Kura Oncology, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 67.48 m USD |
| Operating income | -303.63 m USD |
| EBIT | -276.86 m USD |
| Net income | -278.67 m USD |
| Diluted EPS – continuing operations | -3.18 USD |
Full history since 2008, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Kura Oncology, Inc.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
More stocks
- Liaoning Hongyang Energy Resource Invest Co Ltd (600758.SS)
- Banca IFIS SpA (IF.MI)
- Olema Pharmaceuticals, Inc. (OLMA)
- Cuckoo Electronics Co Ltd (192400.KS)
- GERON CORP (GERN)
- Eos Energy Enterprises, Inc. (EOSE)
- Qingmu Digital Technology Co.Ltd. (301110.SZ)
- Sichuan Discovery Dream Science & Technology Co.Ltd (301213.SZ)
- Shenzhen Kiwi Instruments Co. Ltd. A (688045.SS)
- Shanghai Amarsoft Information & Technolgy Co Ltd (300380.SZ)
- Beijing Jiaxun Feihong Electrical Co Ltd (300213.SZ)
- San Yang Ma (Chongqing) Logistics Co.Ltd. (001317.SZ)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.